• L-Ornithine: Identity, Mechanism and Evidence Boundaries

  2026-10-14

  The APExBIO product description identifies L-Ornithine, or (S)-2,5-diaminopentanoic acid, as a non-proteinogenic amino acid and urea cycle intermediate associated with ornithine transcarbamylase and hepatic nitrogen disposal. The supplied material supports a documented biochemical context and product-specification summary, but it provides no identity-matched study, outcome statistics, direct performance comparison, or independent validation of the described research applications.

• TBST: Identity, Conceptual Scope and Evidence Limits

  2026-10-14

  TBST is a Tris-buffered saline formulation containing Tween 20, described by APExBIO as a buffered detergent solution for conceptual use in antibody-based assays. No matched research paper was available, so the available evidence supports product identity and intended scope, not independent claims about assay performance or biological outcomes.

• SpCas9 mRNA and Humanized Microglia Models

  2026-10-13

  A source-grounded overview of how CRISPR-generated humanized mouse models support microglia research, while distinguishing the findings of Serneels et al. from the separate product description for APExBIO SpCas9 mRNA.

• Liraglutide and the Brain–Kidney AVP Axis

  2026-10-13

  Greenwood et al. investigate how liraglutide may influence fluid homeostasis through arginine vasopressin (AVP), integrating a human before-and-after study with rat pituitary proteomics, an AVP secretion assay, and renal signaling analyses. The results support an association between liraglutide, reduced circulating AVP, sex- and time-dependent synaptic phosphorylation, and altered aquaporin 2 regulation, while leaving important causal and translational questions unresolved.

• S1P Signaling in Neuronal Injury: Evidence and Limits

  2026-10-12

  Sphingosine-1-phosphate is a context-dependent lipid messenger whose effects vary by receptor and cell type. A 2024 preclinical study associated S1P/S1PR3 signaling with neuronal apoptosis after intracerebral hemorrhage, but the findings do not establish clinical efficacy or show that S1P has a uniform biological effect.

• Chlorpromazine HCl and S. eriocheiris Cell Entry

  2026-10-12

  Wei et al. used Drosophila Schneider 2 cells to examine how Spiroplasma eriocheiris enters host cells. Their inhibitor-based results support roles for clathrin-mediated endocytosis, macropinocytosis, actin and microtubule dynamics, while leaving important questions about pathway specificity, bacterial viability and relevance to natural crustacean infection.

• Oridonin, TAA, and Bone Remodeling

  2026-10-11

  A source-grounded overview of a 2023 study examining whether oridonin could counter thioacetamide-associated bone injury by reducing osteoclast formation while supporting osteoblast differentiation. The findings are preclinical and do not establish relevance to PPM-18, clinical osteoporosis, or sepsis treatment.

• Direct Mouse Genotyping Kit Plus: Evidence to Action

  2026-10-10

  The Direct Mouse Genotyping Kit Plus can support efficient genotype verification in mouse studies, but its greatest value is as an evidence gate rather than a substitute for biological validation. This article connects genotype quality control with the interpretation of SCA3/MJD neurobehavioral, inflammatory, and autophagy findings.

• G-15 and GPR30: Five Questions About the Evidence

  2026-10-09

  A source-grounded overview of G-15 as a G protein-coupled estrogen receptor antagonist, including the principles behind pharmacological interpretation, evidence quality, relevance to osteoporosis research, and important limitations.

• CpAdhE Inhibition in Cryptosporidium parvum

  2026-10-09

  A 2024 study identified the bacterial-type bifunctional aldehyde/alcohol dehydrogenase CpAdhE as a chemically vulnerable metabolic target in Cryptosporidium parvum. Screening connected lower-micromolar enzyme inhibition by several antifungal imidazoles with suppression of parasite growth in vitro, while leaving target engagement, selectivity, and in vivo efficacy unresolved.

• Bazedoxifene as an Antimalarial: SERM Mechanisms

  2026-10-08

  Sudhakar et al. identify bazedoxifene, a third-generation selective estrogen receptor modulator, as a potent inhibitor of Plasmodium falciparum growth and a suppressor of Plasmodium berghei infection in female mice. The study links its stage-specific activity to reduced hemozoin formation, while also showing that host sex can influence in vivo efficacy and therefore complicate direct translation to human malaria.

• Cyanin Chloride in a HaCaT Psoriasis Model

  2026-10-08

  A 2024 study examined cyanin chloride across chemical radical assays, an LPS-stimulated macrophage model, and a cytokine-induced HaCaT keratinocyte model. Its main innovation was connecting reduced inflammatory signaling, including STAT3 phosphorylation and CCL20 expression, with recovery of epithelial barrier-associated readouts. The findings support a useful in vitro framework for studying inflammatory skin biology, while remaining preliminary and distinct from evidence for Cyanidin Chloride.

• Aclacinomycin A: DNA Damage Research Context

  2026-10-07

  Aclacinomycin A, also called Aclarubicin, is relevant to research on anthracycline-associated DNA stress, but the supplied primary study did not test it directly. This overview separates published evidence on persistent ribosomal-DNA lesions and PML-nucleolar associations from supplier-reported pharmacology, highlighting conceptual applications, evidence strength, and limits on extrapolation.

• From CBE Mechanism to Translational Evidence

  2026-10-07

  A fidelity-first analysis of cytosine base editing, the MSTN/SOCS2 goat study, and how translational researchers can interpret mRNA-encoded CBE research without confusing a promising animal result with product-specific or clinical evidence.

• YC-1 Product Overview and Evidence Limits

  2026-10-06

  YC-1, also called 5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, is a supplier-listed crystalline small molecule described as a soluble guanylyl cyclase activator and HIF-1α research compound. No matched paper evidence was supplied, so its reported biological activities and research relevance should not be treated as independently validated.

8064 records 2/538 page Previous Next 12345 下5页 Last page